Botulizm ve tanısal yaklaşım

Nöroparalitik bir hastalık olan botulizmi oluşturan Clostridium botulinum biyolojik silah sınıflandırmasındayer aldığı için son yıllarda ayrı bir ilgi çekmektedir. Rutin laboratuar testleri ile botulizm tanısını koymak mümkün değildir. Dışkı ve gıdalardan kültür ile aynı örneklerden ve hasta serumundan toksin aranması tercih edilen işlemlerdir. Tedavide erken tanı ve destekleyici tedavi önemlidir. Botulizm ihbarı zorunlu hastalıklardandır. Çok öldürücü toksini olan bu ajanın, göz ardı edilmemesi ve laboratuar analizleri esnasında biyogüvenlik tedbirlerine uyulması gerekmektedir.

Botulism and diagnostic approach

Clostridium botulinum which causes botulism, a neuroparalytic disease, attracts attention recently because of having an important role on classification of biological warfare agents. The diagnosis of botulism is not possible with routine laboratory tests. Culture from stool and food samples or toxin detection from the same samples and sera are preferable procedures. Early diagnosis and supportive treatment are important. Botulism is a notice required disease.This agent which has a much lethal toxin must be considered important and the employee must comply with the biosafety measures during laboratory testing.

___

  • 1Caya JG, Agni R, Miller JE. Clostridium botulinum and clinical laboratorian. Arch Pathol Lab Med. 2004; 128(6): 653-662.
  • 2 Rega PP, Bork CE, Burkholder-Allen K, Bisesi MS, Gold JP. Single-Breath-Count Test: an important adjunct in the triaging of patients in a mass-casualty incident due to botulism. Prehosp Disaster Med. 2010; 25(3): 219-222.
  • 3 Prigent J, Mazuet C, Boquet D, et al. Production and Characterisation of a Neutralising Chimeric Antibody against Botulinum Neurotoxin A. Plos One. 2010; 5(10): 1-10.
  • 4 Gutzwiller FS, Steffen R, Mathys P, Walser S, Schmid H, Mütsch M. Botulism: prevention, clinical diagnostics, therapy and possible threat. Dtsch Med Wochenschr. 2008; 133(16): 840-845.
  • 5 Willke Topçu A, Söyletir G, Doğanay M. Enfeksiyon Hastalıkları ve Mikrobiyolojisi. I Cilt. Sistemlere Göre Enfeksiyonlar. 3. Baskı. İstanbul. Nobel Tıp Kitabevleri, 2008, p. 1477-1483.
  • 6 Willke A. Botulism. Türkiye Klinikleri j Int Med Sci. 2006; 2(28): 106-112.
  • 7 Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG. Botulinum toxin as a biological weapon: Medical and public health management. JAMA. 2001; 285(8): 1059-1070.
  • 8 Goonetilleke A, Harris JB. Clostridial neurotoxins. J Neurol Neurosurg Psychiatry. 2004; 75: 35-39.
  • 9 Shapiro RL, Hatheway C, Becher J, Swerdlow DL. Botulism surveillance and emergency response. A public health strategy for a global challenge. JAMA. 1997; 278(5): 433-435.
  • 10 Eubanks LM, Silhar P, Salzameda NT, et al. Identification of a Natural Product Antagonist against the Botulinum Neurotoxin Light Chain Protease. ACS Medicinal Chemistry Letters. 2010; 1(6): 268-272.
  • 11 Akçelik M, Ayhan K, Çakır İ, et al. Food Microbiology and Applications. 2. Baskı. Ankara: Sim Matbaacılık Ltd. Şti, 2000, p. 88-92 ve 433-444.
  • 12 Turkish Standard. Mamul Gıdalar İhtisas Grubu. Microbiology–Detection of Clostridium botulinum and identification of spor and toksine types. TS 12812, 2002, p. 2-7.
  • 13 Johnson EA, Summanen P, Finegold SM. Clostridium. Eds.: Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA. Manual of Clinical Microbiology. 9th ed. Washington DC. ASM Pres, 2007, p. 889-910.
  • 14 Ekong T. Immunological detection of botulinum neurotoxins. Anaerobe. 2000; 6(2): 125-127.
  • 15 Chao H, Wang Y, Tang S, Liu H. A highly sensitive immuno-polymerase chain reaction assay for Clostridium botulinum neurotoxin type A. Toxicon. 2004; 43(1): 27-34.
  • 16 Fach P, Hauser D, Guillou JP, Popoff MR. Polymerase chain reaction for the rapid identification of Clostridium botulinum type A strains and detection in food samples. J Appl Bacteriol. 1993; 75(3): 234-239.
  • 17 Szabo EA, Pemberton JM, Desmarchelier PM. Detection of the genes encoding botulinum neurotoxin types A to E by the polymerase chain reaction. Applied and Environmental Microbiology. 1993; 55(9): 3011-3020.
  • 18 Takeshi K, Fujinaga Y, Inoue K, et al. Simple method for detection of Clostridium botulinum type A to F neurotoxin genes by polymerase chain reaction. Microbiol Immunol. 1996; 40(1):5-11.
  • 19 Akbulut D, Grant KA, McLauchilin J. Development and application of real-time PCR assays to detect fragments of the Clostridium botulinum type A, B, and E neurotoxin genes for investigation of human foodborn and infant botulism. Foodborn Pathog Dis. 2004; 1(4): 247-257.
  • 20 Akbulut D, Grant KA, McLauchilin J. Improvement in laboratory diagnosis of wound botulism and tetanus among injecting illicit-drug users by use of real-time PCR assays for neurotoxin gene fragments. J Clin Microbiol. 2005; 43(9): 4342-4348.
  • 21 Franciosa G, Pourshaban M, Luca AD, Buccino A, Dallapiccola B, Aureli P. Identification of type A, B, E and F botulinum neurotoxin genes and af botulinum neurotoxigenic clostridia by denaturing high-performance liquid chromatography. Applied and Environmental Microbiology. 2004; 70(7): 4170-4176.
  • 22 Swenson JM, Thornsberry C, McCroskey LM, Hatheway CL, Dowell VR. Susceptibility of Clostridium botulinum to thirteen antimicrobial agents. Antimicrobial Agents and Chemotherapy. 1980; 18(1): 13-19.
  • 23 Dezfulian M, Dowell VR. Cultural and physiological characteristics and antimicrobial susceptibility of Clostridium botulinum isolates from foodborne and infant botulism cases. Journal of Clinical Microbiology. 1980; 11(6):604-609